Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet hyperactivity after statin treatment discontinuation.

Luca Puccetti1, Anna Laura Pasqui, Marcello Pastorelli

  • 1Department of Clinical Medicine and Immunological Sciences, Internal Medicine Division, Policlinico Le Scotte, V. le Bracci, 53100, Siena, Italy. puccetti@unisi.it

Thrombosis and Haemostasis
|September 6, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left ventricular excessive trabeculation: pathophysiology, diagnostic challenges, and prognostic significance.

Heart failure reviews·2026
Same author

Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.

Heart failure reviews·2026
Same author

Across Clinical Profiles of Cardiorenal-Metabolic (CKM) Syndrome: A Phenotype-Driven Therapeutic Approach.

Biomedicines·2026
Same author

The spectrum of congestion in heart failure: underlying pathophysiology and diagnostic strategies.

Heart failure reviews·2026
Same author

Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.

Heart failure reviews·2026
Same author

MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.

British journal of haematology·2026

Statin discontinuation leads to increased platelet activity and cardiovascular risk, linked to higher LDL-C. Continuing statin treatment maintains normal platelet function, highlighting the importance of statins for vascular protection.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Statins (HMG-CoA reductase inhibitors) reduce cardiovascular events through lipid-lowering and non-lipid mechanisms.
  • Modulation of platelet activity is a key non-lipid action of statins in vascular protection.
  • Statin withdrawal is associated with an increased cardiovascular event rate.

Purpose of the Study:

  • To evaluate platelet activity following cerivastatin discontinuation.
  • To compare platelet activity in subjects discontinuing statins versus those continuing simvastatin.
  • To investigate the relationship between lipid profile, oxidized-LDL, and platelet activation markers post-statin.

Main Methods:

  • Assessed lipid profile, oxidized-LDL (ox-LDL), platelet P-selectin (P-sel) expression, platelet aggregation, and intracellular citrulline (iCit) production.

Related Experiment Videos

  • Measurements were taken at baseline and at 7, 14, 28, and 60 days after statin discontinuation.
  • Compared outcomes between subjects discontinuing statins, continuing simvastatin, and those restarting simvastatin after a washout period.

    • Main Results:

    • Platelet P-selectin expression and aggregation significantly increased 14 days after statin discontinuation.
    • Increased platelet activity correlated with elevated ox-LDL and reduced iCit (NO synthase activity).
    • Higher LDL-C levels at 28 days were associated with increased P-sel and platelet aggregation.

    Conclusions:

    • Statin discontinuation induces a state of platelet hyperactivation within two weeks, partly due to elevated LDL-C.
    • This hyperactivation state may contribute to the increased cardiovascular event rate observed after statin withdrawal.
    • Continuous statin therapy, exemplified by simvastatin, preserves normal platelet function and vascular protection.